Scarica l'app Stockscreener
0.723
0.25%
0.0018
Dopo l'orario di chiusura:
.72
-0.003
-0.41%
Precedente Chiudi:
$0.7212
Aprire:
$0.7484
Volume 24 ore:
664.20K
Relative Volume:
0.34
Capitalizzazione di mercato:
$108.63M
Reddito:
-
Utile/perdita netta:
$-225.14M
Rapporto P/E:
-0.3689
EPS:
-1.96
Flusso di cassa netto:
$-192.27M
1 W Prestazione:
+2.66%
1M Prestazione:
-22.26%
6M Prestazione:
+50.62%
1 anno Prestazione:
-34.27%
Intervallo 1D:
$0.723
$0.77
Intervallo di 1 settimana:
$0.71
$0.8196
Portata 52W:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Nome
Invivyd Inc
Settore
Industria
Telefono
(781) 819-0080
Indirizzo
1601 TRAPELO ROAD, WALTHAM
Confronta IVVD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
0.723 | 108.63M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-04-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2024-03-26 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-05-01 | Iniziato | H.C. Wainwright | Buy |
Invivyd Inc Borsa (IVVD) Ultime notizie
Trading Day Triumph: Invivyd Inc (IVVD) Ends at 0.79, a -6.47 Surge/Plunge - DWinneX
H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall - Insider Monkey
Invivyd stock target cut to $5 by H.C. Wainwright, retains Buy rating - Investing.com Nigeria
Invivyd (NASDAQ:IVVD) Price Target Lowered to $5.00 at HC Wainwright - Defense World
Invivyd (IVVD) Analyst Rating Update: Price Target Lowered | IVV - GuruFocus
Invivyd (IVVD) Price Target Reduced by H.C. Wainwright Amid Revenue Concerns | IVVD Stock News - GuruFocus
Invivyd (IVVD) Publishes Strong Phase 3 Trial Results for COVID-19 Antibody | IVVD Stock News - GuruFocus
Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive S - The Manila Times
Breakthrough COVID-19 Drug PEMGARDA Achieves 84% Protection in First Modern U.S. Phase 3 Trial - Stock Titan
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP By Investing.com - Investing.com South Africa
Invivyd’s antibody gains spot in cancer guidelines for COVID-19 PrEP - Investing.com Australia
Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas - marketscreener.com
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas - The Manila Times
Invivyd (IVVD) Monoclonal Antibody Added to NCCN Guidelines for B-Cell Lymphomas | IVVD Stock News - GuruFocus
NCCN Guidelines Now Include PEMGARDA for B-Cell Lymphoma COVID Protection | IVVD Stock News - Stock Titan
Invivyd (IVVD) Applauds FDA's Steps to Address COVID-19 Booster Uncertainty | IVVD Stock News - GuruFocus
Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19 - The Manila Times
Invivyd Commends FDA on New Framework for COVID-19 Vaccines Amidst Uncertainty Regarding Booster Efficacy - Nasdaq
FDA Questions COVID Booster Benefits While Invivyd's Antibody Shows 84% Protection in Modern Trials - Stock Titan
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies By Investing.com - Investing.com Nigeria
Invivyd Holds Annual Stockholders Meeting, Elects Directors - TipRanks
Invivyd at H.C. Wainwright Conference: Strategic Moves in Antibodies - Investing.com
Upstream Bio Strengthens Leadership Team: Former Invivyd Executive Takes CTO Role for Critical Clinical Program - Stock Titan
Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | I - GuruFocus
Invivyd, Inc. (NASDAQ:IVVD) Q1 2025 Earnings Call Transcript - Insider Monkey
Invivyd Q1 2025 slides: Revenue grows amid regulatory hurdles and cash concerns - Investing.com Nigeria
Invivyd (IVVD) Maintains Buy Rating with Stable Price Target | IVVD Stock News - GuruFocus
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss - Investing.com Canada
Earnings call transcript: Invivyd Q1 2025 sees stock drop amid earnings miss By Investing.com - Investing.com South Africa
Invivyd Reports Q1 2025 Financial Results and Outlook - TipRanks
Invivyd’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Why JD.com Stock Slumped on Thursday - The Globe and Mail
INVIVYD SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc.IVVD, A - Barchart.com
Transcript : Invivyd, Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strate - GuruFocus
Invivyd (IVVD) Reports Q1 Revenue Below Expectations Amid Strategic Shift | IVVD Stock News - GuruFocus
Invivyd Reports Q1 2025 Financial Results and Highlights - TipRanks
INVIVYD Earnings Results: $IVVD Reports Quarterly Earnings - Nasdaq
Invivyd, Inc. SEC 10-Q Report - TradingView
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Invivyd, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Invivyd calls for modernized FDA vaccine guidelines By Investing.com - Investing.com Canada
Invivyd Launches New Measles Antibody Discovery Program: Retail Traders Bet On ‘Future Of Medicine’ - MSN
What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings - Yahoo Finance
Invivyd Inc Azioni (IVVD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Invivyd Inc Azioni (IVVD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MCGUIRE TERRANCE | Director |
Dec 27 '24 |
Sale |
0.52 |
83,744 |
43,647 |
3,256,776 |
| MCGUIRE TERRANCE | Director |
Dec 30 '24 |
Sale |
0.48 |
86,545 |
41,784 |
3,170,231 |
| MCGUIRE TERRANCE | Director |
Dec 20 '24 |
Sale |
0.42 |
119,805 |
50,725 |
3,568,274 |
| MCGUIRE TERRANCE | Director |
Dec 26 '24 |
Sale |
0.54 |
83,817 |
45,563 |
3,340,520 |
| MCGUIRE TERRANCE | Director |
Dec 24 '24 |
Sale |
0.51 |
68,161 |
34,503 |
3,424,337 |
| MCGUIRE TERRANCE | Director |
Dec 23 '24 |
Sale |
0.45 |
75,776 |
34,076 |
3,492,498 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):